List of Excipients in Branded Drug VAPRISOL DEXTROSE IN PLASTIC CONTAINER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cumberland Pharmaceuticals Inc	VAPRISOL DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	66220-160	DEXTROSE
Cumberland Pharmaceuticals Inc	VAPRISOL DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	66220-160	LACTIC ACID

VAPRISOL DEXTROSE IN PLASTIC CONTAINER: EXCIPIENT STRATEGY, FORMULATION IP, AND COMMERCIAL OPPORTUNITIES

Last updated: August 9, 2026

VAPRISOL Dextrose in Plastic Container is a premixed intravenous formulation of conivaptan hydrochloride in 5% dextrose injection. Its commercial value is driven less by complex excipient technology than by ready-to-use presentation, hospital workflow, compatibility control, and the ability to support controlled hospital distribution. The core formulation is relatively accessible to generic developers, but container compatibility, precipitation control, stability, and clinical-use labeling remain practical barriers.

What is VAPRISOL Dextrose in Plastic Container?

VAPRISOL is an intravenous vasopressin V1A/V2 receptor antagonist approved for treatment of euvolemic and hypervolemic hyponatremia in hospitalized adults. The product is supplied as a single-use, 100 mL flexible plastic container containing 20 mg of conivaptan hydrochloride in 5% dextrose injection.[1]

Product attribute	VAPRISOL Dextrose in Plastic Container
Active ingredient	Conivaptan hydrochloride
Therapeutic class	Vasopressin receptor antagonist
Route	Intravenous infusion
Strength	20 mg per 100 mL
Active concentration	0.2 mg/mL
Diluent	5% dextrose injection
Container	Single-use flexible plastic container
Approved indication	Euvolemic or hypervolemic hyponatremia
Loading dose	20 mg over 30 minutes
Maintenance dose	20 mg daily by continuous infusion
Maximum treatment duration	Four days
Regulatory application	U.S. NDA 021697

The product is administered through a controlled infusion rather than as an intravenous bolus. Its premixed presentation removes bedside dilution and reduces preparation steps.

What excipients are used in VAPRISOL Dextrose?

The principal excipient system is 5% dextrose in water, with hydrochloric acid used for pH adjustment. The formulation is not a conventional isotonic saline product. The dextrose vehicle provides osmotic support and functions as the infusion medium.

The formulation strategy can be summarized as follows:

Formulation component	Function	Commercial relevance
Dextrose	Infusion vehicle and osmotic agent	Enables a ready-to-use premixed bag
Water for injection	Solvent	Supports parenteral quality requirements
Hydrochloric acid	pH adjustment	Helps control solubility and chemical stability
Conivaptan hydrochloride	Active pharmaceutical ingredient	Requires control of concentration, pH, and container interaction

The label identifies the product as a sterile, clear solution. The formulation does not depend on a proprietary lipid system, polymeric depot, liposome, surfactant platform, or lyophilized reconstitution process.[1]

Why does the dextrose vehicle matter commercially?

The dextrose vehicle supports hospital-use convenience and differentiates the product from a vial requiring dilution. A premixed infusion can reduce pharmacy compounding activity, limit dilution errors, and simplify administration in intensive-care and inpatient settings.

The commercial tradeoff is that dextrose is not universally suitable for every hospitalized patient. Prescribers may need to account for hyperglycemia, diabetes management, fluid restrictions, and total carbohydrate exposure. A saline-based presentation could address some of those use cases, but it would require a separate formulation and regulatory filing.

The dextrose presentation also creates a product-positioning opportunity for manufacturers that can offer:

• A ready-to-administer 100 mL bag
• A smaller-volume presentation for fluid-restricted patients
• A vial or ampule for institution-controlled dilution
• A saline-compatible alternative
• A preservative-free hospital formulation
• A dual-source product with improved supply reliability

What technical barriers does the plastic container create?

The flexible plastic container is a functional component of the product, not merely packaging. A generic or follow-on manufacturer must establish that the container does not compromise potency, purity, sterility, or infusion performance.

Container-closure compatibility

Conivaptan and its impurities must be evaluated for interaction with the bag, ports, tubing, and administration set. Relevant risks include adsorption to plastic surfaces, permeation, extractables, leachables, and changes in solution clarity.

The container assessment normally covers:

• Extractables and leachables
• Sorption of conivaptan to container materials
• Moisture and oxygen transmission
• Seal integrity
• Particulate generation
• Port compatibility
• Compatibility with standard infusion tubing
• Stability under shipping and storage conditions

A flexible plastic system can improve handling and reduce breakage compared with glass, but it introduces a larger material-contact surface and greater dependence on polymer composition.

pH and precipitation control

The product is an aqueous concentrate of a hydrochloride salt in a dextrose vehicle. pH control is central to maintaining solubility and chemical stability. An alternative excipient system may change the ionization state of conivaptan, alter precipitation risk, or produce a different impurity profile.

Generic developers should treat pH as a critical quality attribute. A formulation that matches the nominal active concentration but uses a different pH range or buffer system may require extensive comparative stability and compatibility work.

Dextrose degradation

Dextrose solutions can undergo degradation during prolonged storage or exposure to heat. The formulation must be assessed for color change, degradation products, particulate formation, and interactions with the active ingredient. Terminal sterilization, aseptic processing, storage temperature, and shipping conditions can affect the stability profile.

What formulations are protected by VAPRISOL-related intellectual property?

The practical IP position is likely narrower today than during the product’s launch period because the original conivaptan patent estate and regulatory exclusivities have largely aged out. The commercial barriers now center on formulation know-how, manufacturing controls, regulatory data, and hospital procurement rather than broad composition-of-matter exclusivity.

Relevant protection categories include:

IP category	Potential scope	Current commercial impact
Composition of matter	Conivaptan molecule and salts	Likely expired or commercially weak in the U.S.
Therapeutic use	Treatment of hyponatremia or related conditions	May have limited value because of label and timing constraints
Injectable formulation	Concentration, pH, vehicle, and stability	Potentially relevant only if unexpired claims remain
Container system	Bag, port, material, or closure configuration	Usually narrow and design-around capable
Manufacturing process	Sterile processing, filtration, filling, and controls	Often protected as know-how rather than enforceable broad patent rights
Stability package	Shelf-life and storage conditions	Regulatory asset, not necessarily patent exclusivity

The FDA Orange Book should be checked for active patents listed against NDA 021697 before relying on any conclusion about current U.S. patent protection.[2] A generic applicant would also need to assess Paragraph IV exposure if any unexpired listed patent remains relevant to the proposed product.

When does VAPRISOL lose exclusivity?

VAPRISOL received FDA approval in 2005. The principal period of U.S. regulatory exclusivity has expired. New chemical entity exclusivity generally lasts five years from approval, subject to statutory exceptions, while orphan-drug exclusivity applies only if the product received orphan designation and approval for the orphan indication.[3]

The remaining commercial question is not whether the original exclusivity period is active. It is whether any unexpired patent, regulatory restriction, supply agreement, or technical barrier limits an abbreviated new drug application or another competitive pathway.

Milestone	Date or status
FDA approval	December 2005
Five-year NCE exclusivity	Expired
Original commercial launch period	Expired
Current competitive assessment	Patent and market-entry review required
Primary regulatory pathway for a generic	ANDA, subject to reference-product availability and Orange Book status

What FDA regulatory issues affect a generic VAPRISOL product?

A generic developer would likely pursue an ANDA if the reference product and applicable dosage form remain eligible for that pathway. The submission would need to address pharmaceutical equivalence, bioequivalence requirements applicable to an injectable product, sterility, container-closure integrity, particulate matter, impurities, pH, osmolality, and stability.

For an aqueous intravenous product, the key development questions include:

1. Whether the proposed product matches the active concentration and dosage form.
2. Whether the proposed container is pharmaceutically equivalent and suitable for infusion.
3. Whether the formulation contains the same or permissible differences in inactive ingredients.
4. Whether the product remains stable through the proposed shelf life.
5. Whether the labeling preserves the approved administration instructions and warnings.

The product label includes clinically important restrictions involving CYP3A4 interactions, infusion-site reactions, hypotension, renal impairment, and rapid correction of serum sodium.[1] A generic manufacturer must reproduce the reference labeling framework while complying with applicable FDA labeling requirements.

How strong is the formulation patent estate for VAPRISOL?

The formulation patent estate appears commercially moderate to weak unless an unexpired patent claims a specific container, pH range, stability profile, or manufacturing process. The base concept, conivaptan hydrochloride in an aqueous dextrose infusion, is comparatively straightforward to reproduce.

The strongest practical barriers are likely:

• Control of conivaptan-related impurities
• Demonstration of long-term stability
• Plastic-container extractables and leachables
• Infusion-set compatibility
• Sterile manufacturing validation
• Scale-up of a low-volume hospital product
• Reliable access to active pharmaceutical ingredient
• Commercial economics at low annual unit volumes

These barriers can delay entry without creating durable exclusivity. They favor manufacturers with existing sterile injectable capacity, flexible-bag manufacturing, and hospital sales infrastructure.

Which companies could challenge VAPRISOL?

Potential challengers would include generic injectable manufacturers with hospital distribution and flexible-container capabilities. Relevant strategic groups include:

• Large generic injectable manufacturers
• Contract development and manufacturing organizations
• Hospital-focused specialty pharmaceutical companies
• Regional sterile-injectable suppliers
• Manufacturers seeking portfolio products for hyponatremia and critical-care use

The product’s limited indication and short four-day treatment duration may reduce market size. That makes VAPRISOL more attractive as a portfolio product than as a standalone commercial platform.

A challenger could pursue one of three approaches:

Entry strategy	Advantages	Limitations
Direct 20 mg/100 mL generic	Closest substitution and simplest hospital formulary review	Direct price competition
Alternative vial presentation	Lower packaging cost and more flexible use	Requires bedside dilution and may lose convenience
New premixed saline or lower-volume bag	Differentiated clinical positioning	Likely requires a new regulatory strategy

What commercial opportunities exist for excipient and container suppliers?

The strongest opportunities are in enabling technologies rather than novel excipients. Suppliers can create value through validated materials and manufacturing systems that reduce development and regulatory risk.

Flexible plastic container systems

A supplier with a qualified non-PVC or multilayer bag system could target conivaptan and other acidic intravenous formulations. The value proposition would include low extractables, low adsorption, high seal integrity, and compatibility with standard infusion sets.

Ready-to-use infusion platforms

A manufacturer could use a common 100 mL premix platform for hospital drugs requiring controlled infusion. Shared filling, inspection, labeling, and distribution infrastructure could improve economics across a portfolio.

Excipient and pH-control packages

A standardized dextrose, water-for-injection, and pH-adjustment system could reduce development time for products with similar aqueous stability requirements. The commercial opportunity is strongest where the supplier can provide regulatory documentation, not merely raw materials.

Smaller-volume presentations

A 50 mL bag or concentrated vial could target fluid-restricted patients. The formulation would need to preserve dose accuracy and stability while reducing total fluid burden. This opportunity has clinical logic but may require a separate product strategy rather than a simple generic substitution.

What manufacturing and IP barriers could limit generic launch?

The main launch risks are technical and economic. A manufacturer may obtain regulatory approval yet face weak commercial returns if demand is concentrated in a small number of hospitals.

Potential barriers include:

• Limited API suppliers
• Low production volumes
• High sterile-manufacturing costs
• Complex quality-control testing
• Container qualification requirements
• Hospital contracting pressure
• Reference-product discontinuation or supply instability
• Limited clinical demand outside specialist inpatient settings

A Paragraph IV challenge would have value only if an unexpired Orange Book-listed patent creates a credible litigation risk. If no relevant listed patent remains, the principal generic-entry work shifts to ANDA development, facility readiness, and commercial contracting.

How does VAPRISOL compare with alternative hyponatremia products?

VAPRISOL competes with oral and intravenous approaches to hyponatremia, including fluid restriction, hypertonic saline, and oral vasopressin antagonists such as tolvaptan. Its differentiator is controlled intravenous delivery in hospitalized patients.

Product or approach	Route	Primary advantage	Commercial limitation
VAPRISOL	IV infusion	Hospital-controlled parenteral administration	Short treatment course and monitoring burden
Tolvaptan	Oral	Oral administration and broader familiarity	Hepatic monitoring and cost considerations
Hypertonic saline	IV	Rapid sodium correction in selected cases	Intensive monitoring and correction-risk management
Fluid restriction	Oral/supportive care	Low drug cost	Slow or inadequate response in some patients

VAPRISOL’s most defensible commercial position is as a hospital-use injectable for selected patients who require pharmacologic correction and cannot rely on fluid restriction alone.

What is the revenue exposure and market opportunity?

Public sources do not provide a reliable current product-level revenue figure for VAPRISOL. The addressable market is constrained by the short maximum treatment duration, inpatient administration, specialist prescribing, and competition from established treatment protocols.

Commercial opportunity is more credible in the following areas:

• Supply-secure generic entry
• Hospital contract portfolios
• 100 mL premixed bags
• Alternative container platforms
• Regional markets with limited injectable competition
• Contract manufacturing for specialty hospital products
• Lifecycle reformulation for fluid-restricted patients

A generic launch would likely depend on low-cost sterile manufacturing and portfolio leverage. A premium branded reformulation would need a clinically meaningful advantage, such as lower fluid volume, improved compatibility, or easier administration.

Key Takeaways

• VAPRISOL Dextrose in Plastic Container is a 20 mg/100 mL premixed conivaptan hydrochloride infusion in 5% dextrose.
• The excipient system is simple, but pH, precipitation, impurity control, and container compatibility are critical.
• The flexible plastic container creates technical requirements involving extractables, leachables, adsorption, seal integrity, and infusion-set compatibility.
• Original U.S. regulatory exclusivity has expired. Current entry analysis depends on Orange Book patents, reference-product status, and ANDA feasibility.
• Formulation and container patents are likely narrower and more design-around capable than molecule patents.
• The strongest commercial opportunity is a hospital-focused generic or a differentiated premixed presentation backed by sterile-injectable manufacturing capacity.
• A saline formulation, smaller-volume bag, or vial could create lifecycle opportunities but may require a separate regulatory strategy.
• Market potential is limited by short treatment duration, inpatient use, clinical monitoring, and competition from tolvaptan and hypertonic saline.

FAQs

Can VAPRISOL be reformulated in normal saline?

A saline formulation would require formulation development and regulatory review. It cannot be assumed to be therapeutically or pharmaceutically equivalent to the approved dextrose presentation.

Is the VAPRISOL plastic container itself patent-protected?

Container protection, if any, would generally depend on specific material, port, closure, or packaging claims. The operative status should be verified through current U.S. patent and Orange Book records.

Is conivaptan available as an oral drug?

VAPRISOL is an intravenous product. Its approved U.S. product presentation is not an oral dosage form.

What is the main stability risk for a generic VAPRISOL bag?

The principal risks are active degradation, precipitation, pH drift, container interaction, extractables and leachables, and particulate formation during storage.

Would a VAPRISOL biosimilar be possible?

No. Conivaptan is a small-molecule drug, so a competing product would generally use a generic-drug pathway rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2005). VAPRISOL (conivaptan hydrochloride) injection prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2018). Small business assistance: Frequently asked questions on the new drug application process.